ATE530188T1 - Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs - Google Patents
Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebsInfo
- Publication number
- ATE530188T1 ATE530188T1 AT08714327T AT08714327T ATE530188T1 AT E530188 T1 ATE530188 T1 AT E530188T1 AT 08714327 T AT08714327 T AT 08714327T AT 08714327 T AT08714327 T AT 08714327T AT E530188 T1 ATE530188 T1 AT E530188T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- cancer agents
- delivering anti
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90436307P | 2007-03-02 | 2007-03-02 | |
| PCT/AU2008/000276 WO2008106721A1 (en) | 2007-03-02 | 2008-02-29 | Compositions and methods for delivery of anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530188T1 true ATE530188T1 (de) | 2011-11-15 |
Family
ID=39737685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08714327T ATE530188T1 (de) | 2007-03-02 | 2008-02-29 | Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8372834B2 (de) |
| EP (1) | EP2131849B1 (de) |
| CN (1) | CN101657203B (de) |
| AT (1) | ATE530188T1 (de) |
| AU (1) | AU2008222592B2 (de) |
| CA (1) | CA2679919C (de) |
| ES (1) | ES2373867T3 (de) |
| WO (1) | WO2008106721A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2753641C (en) | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8389558B2 (en) | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| DE102009043717A1 (de) * | 2009-10-01 | 2011-04-07 | Westfälische-Wilhelms Universität Münster | Fluorcyclodextrine |
| UA98666C2 (ru) * | 2010-03-25 | 2012-06-11 | Геннадий Васильевич Мазильников | Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
| UA98665C2 (ru) * | 2010-03-25 | 2012-06-11 | Геннадий Васильевич Мазильников | Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| CN104548103B (zh) * | 2013-10-17 | 2018-04-10 | 江西中医药大学 | 氧化石墨烯和氯霉素直接结合的复合物的制备方法 |
| WO2022147743A1 (en) * | 2021-01-08 | 2022-07-14 | Quadriga Biosciences, Inc. | Pharmaceutical compositions of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives |
| US20240342177A1 (en) * | 2021-08-04 | 2024-10-17 | Detsamma Investments Pty Ltd | Methods of treating brain cancer |
| CN114920859B (zh) * | 2022-05-11 | 2023-09-26 | 宁夏医科大学总医院 | 5-氟尿嘧啶-1-丁酰基-β-环糊精第二面衍生物及制备方法及其应用 |
| US12564592B1 (en) * | 2024-12-23 | 2026-03-03 | Riconpharma LLC | Injectable leucovorin formulations and methods of preparing same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| IT1237509B (it) | 1989-10-31 | 1993-06-08 | Magis Farmaceutici | Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5376658A (en) * | 1990-05-11 | 1994-12-27 | University Of Southern California | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| US5427954A (en) * | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
| CH684644A5 (de) | 1992-07-13 | 1994-11-15 | Eprova Ag | 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen. |
| US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| EP0715854B1 (de) | 1994-11-11 | 2003-09-10 | Debiopharm S.A. | Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| AU4564200A (en) * | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| AU2001240001A1 (en) * | 2000-03-08 | 2001-09-17 | Bristol-Myers Squibb Company | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US6620816B2 (en) * | 2001-04-26 | 2003-09-16 | Bristol-Myers Squibb Company | Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide |
| US20040033271A1 (en) * | 2001-12-03 | 2004-02-19 | Seth Lederman | Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| WO2004006859A2 (en) * | 2002-07-16 | 2004-01-22 | Sonus Pharmaceuticals, Inc. | Platinum compound |
| UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| DE10314377A1 (de) | 2003-03-28 | 2004-10-07 | Stada Arzneimittel Ag | Gebrauchsfertige Oxaliplatin-Lösungen |
| CA2427258A1 (en) * | 2003-04-30 | 2004-10-30 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
| US7345046B2 (en) * | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| CA2561952A1 (en) * | 2004-04-02 | 2005-10-20 | Adventrx Pharmaceuticals, Inc. | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
| CN100588428C (zh) | 2005-08-16 | 2010-02-10 | 沈阳药科大学 | 氟尿嘧啶-右旋糖酐偶联物及其制备方法 |
-
2008
- 2008-02-29 AU AU2008222592A patent/AU2008222592B2/en active Active
- 2008-02-29 CA CA2679919A patent/CA2679919C/en active Active
- 2008-02-29 AT AT08714327T patent/ATE530188T1/de not_active IP Right Cessation
- 2008-02-29 EP EP08714327A patent/EP2131849B1/de active Active
- 2008-02-29 WO PCT/AU2008/000276 patent/WO2008106721A1/en not_active Ceased
- 2008-02-29 US US12/529,635 patent/US8372834B2/en active Active
- 2008-02-29 ES ES08714327T patent/ES2373867T3/es active Active
- 2008-02-29 CN CN2008800122995A patent/CN101657203B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2131849B1 (de) | 2011-10-26 |
| CA2679919C (en) | 2015-12-15 |
| EP2131849A1 (de) | 2009-12-16 |
| CA2679919A1 (en) | 2008-09-12 |
| ES2373867T3 (es) | 2012-02-09 |
| EP2131849A4 (de) | 2010-03-24 |
| CN101657203A (zh) | 2010-02-24 |
| AU2008222592B2 (en) | 2013-09-26 |
| US20100063057A1 (en) | 2010-03-11 |
| WO2008106721A1 (en) | 2008-09-12 |
| CN101657203B (zh) | 2012-09-05 |
| AU2008222592A1 (en) | 2008-09-12 |
| US8372834B2 (en) | 2013-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121363T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
| EP2131849A4 (de) | Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs | |
| GEP20105074B (en) | Pyrimidinyl aryl urea derivatives being fgf inhibitors | |
| ATE469158T1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
| CY1116695T1 (el) | Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο | |
| MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
| EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
| ECSP109898A (es) | Compuestos orgánicos | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| MX2009010037A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
| EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
| IN2012DN01641A (de) | ||
| DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
| MX2009011811A (es) | Aminopirimidinas utiles como inhibidores de cinasa. | |
| EA201101650A1 (ru) | Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| MX385354B (es) | Sales de xantilio 3,6-disustituidas. | |
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
| WO2013040227A3 (en) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |